Advancing Diabetes Care: Wearable CGM Market Dynamics and Outlook to 2033 | DataM Intelligence

The wearable continuous glucose monitoring devices market is experiencing lucrative growth due to the rising prevalence of diabetes, increasing awareness among the diabetes population on disease management, and rising innovations from key market players. However, the affordability issues in the low and middle-income countries, accuracy, and calibration issues can hinder the adoption of CGMs at the anticipated rate.
According to a report by DataM Intelligence, Wearable Continuous Glucose Monitoring Devices Market reached US$12.20 billion in 2024 and is expected to reach US$32.48 billion by 2033, growing at a CAGR of 10.3% during the forecast period 2025-2033, according to DataM intelligence research.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response):
https://www.datamintelligence.com/download-sample/wearable-continuous-glucose-monitors-market?vv

Key Highlights from the Report:
➤The global wearable CGM market was valued at US$12.20 billion in 2024, projected to reach US$32.48 billion by 2033 at a CAGR of 10.3%.
➤ North America held a dominant 53.4% market share in 2024, driven by high diabetes prevalence and advanced healthcare infrastructure.
➤ Sensors accounted for 71.4% of the market share in 2024, fueled by demand for accurate, long-lasting, and compact designs.
➤ Key players like Dexcom, Abbott, and Senseonics drive innovation with FDA-approved devices like the G7 15-Day and Eversense 365.
➤ Rising diabetes cases (588.71 million globally in 2024) and increasing awareness boost CGM adoption worldwide.
➤ Accuracy and calibration challenges, alongside affordability issues in low-income regions, may hinder market growth.

Market Segmentation:
By Component
The wearable continuous glucose monitoring (CGM) devices market is segmented by component into receivers or display devices, sensors, transmitters, and others. Sensors dominate, holding 71.4% of the market share in 2024 due to their critical role in providing real-time glucose measurements from interstitial fluid. Innovations in sensor technology, such as extended wear times (e.g., Eversense 365's year-long lifespan) and enhanced accuracy, drive this segment's growth. Receivers and display devices facilitate user interaction by presenting glucose data, while transmitters enable wireless data transfer to smartphones or other devices.

By Indication
Segmentation by indication categorizes the market into Type 1 and Type 2 diabetes. Type 2 diabetes holds a larger share due to its higher global prevalence, with 90-95% of the 588.71 million diabetic cases in 2024 being Type 2, per the International Diabetes Federation. CGMs are increasingly adopted for Type 2 management, especially for non-insulin users, as seen with Dexcom's Stelo biosensor launched in August 2024.

By Age Group
The market is segmented by age group into children, adults, and geriatrics. Adults dominate due to the higher prevalence of diabetes in this demographic, particularly Type 2, driven by lifestyle factors and aging. Geriatrics are a growing segment, with 25% of those over 60 affected by diabetes, per WHO data, necessitating user-friendly CGMs like Abbott's Lingo for elderly patients.

Looking For Full Report? Get it https://www.datamintelligence.com/buy-now-page?report=wearable-continuous-glucose-monitors-market?vv

Regional Insights:
North America:
North America led the global wearable CGM market with a 53.4% share in 2024, driven by a high diabetes prevalence (38 million in the U.S. alone) and advanced healthcare infrastructure. Favorable reimbursement policies and FDA approvals, such as Dexcom's G7 15-Day system in April 2025 and Abbott's OTC Lingo in September 2024, enhance accessibility.

Latin America:
Latin America's wearable CGM market is growing steadily, driven by increasing diabetes prevalence and improving healthcare access. In 2024, the region accounted for a smaller market share due to economic constraints and limited reimbursement policies. Brazil and Mexico are key markets, with rising awareness of CGM benefits among Type 2 diabetes patients.

Europe:
Europe holds a significant share of the wearable CGM market, driven by universal healthcare coverage and high diabetes awareness. Germany leads, with CGM established as the standard for Type 1 diabetes care, while the UK's NHS subsidizes advanced devices. In March 2025, Medtronic launched the Guardian 4 CGM sensor, offering 14-day wear and real-time alarms. Eastern Europe, including Poland and Czechia, is emerging with pilot funding for CGMs in 2025.

Asia Pacific:
Asia Pacific is the fastest-growing region for wearable CGMs, driven by a massive diabetic population (233 million in China alone) and increasing healthcare investments. Japan and South Korea lead with high per-capita CGM uptake, integrating glucose modules into multipurpose wearables. China's market is expanding rapidly, with Dexcom's ONE+ launch in January 2025 and government reimbursement pilots.

Middle East and Africa:
The Middle East and Africa (MENA) region has a smaller but growing wearable CGM market, driven by a high diabetes burden, particularly in Gulf countries. In 2024, MENA's market share was limited by affordability issues and underdeveloped healthcare infrastructure in many areas.The UAE and Saudi Arabia lead adoption due to higher purchasing power and government health initiatives. Awareness campaigns and increasing availability of advanced CGMs, like Abbott's FreeStyle Libre, are boosting growth. However, accuracy concerns and lack of reimbursement in low-income countries restrain market penetration. Strategic partnerships and localized pricing strategies are essential to unlock the region's potential.

Market Dynamics:
Market Drivers
The wearable CGM market is propelled by the rising global prevalence of diabetes, with 588.71 million cases in 2024, projected to reach 852.47 million by 2050, per the International Diabetes Federation. Increasing awareness of diabetes management, particularly among Type 2 patients, drives demand for user-friendly CGMs. Technological advancements, such as smaller, more accurate sensors and integrations with smartphones and insulin pumps, enhance adoption. Favorable reimbursement policies in North America and Europe, along with FDA approvals for OTC devices, expand accessibility.

Market Restraints
Accuracy and calibration issues pose significant challenges, as CGMs rely on interstitial fluid measurements, which can lag behind blood glucose levels by up to 25 minutes, leading to discrepancies during rapid fluctuations. Faulty sensors or transmitters can further compromise reliability, requiring frequent recalibration, which users find cumbersome. High costs, with initial CGM systems ranging from $1,000-$2,000 and monthly sensor expenses of $300-$450, limit adoption in low- and middle-income countries.

Market Opportunities
The wearable CGM market offers substantial opportunities through innovations like non-invasive and longer-lasting sensors, such as the Eversense 365, which reduce user burden. The growing demand for OTC CGMs, as seen with Dexcom's Stelo and Abbott's Lingo, opens markets to non-insulin-dependent users, including those with prediabetes. Emerging markets in Asia Pacific, particularly China and India, present untapped potential due to large diabetic populations and increasing healthcare investments.

Reasons to Buy the Report
• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.

Frequently Asked Questions (FAQs)
• What is the market size of the wearable continuous glucose monitoring devices market?
• Who are the key players in the Global Wearable Continuous Glucose Monitoring Devices Market ?
• What are recent regulatory approvals driving North American growth?
• What innovations are shaping the CGM sensor segment?
• What is driving growth in the CGM devices market?

Company Insights:
• Dexcom Inc.
• Abbott
• Medtronic
• Senseonics
• F. Hoffmann-La Roche Ltd
• Afon Technology

Recent Developments:
FDA Approval of Dexcom's G7 15-Day CGM System
In April 2025, the U.S. FDA approved Dexcom's G7 15-Day continuous glucose monitoring system for adults over 18 with diabetes. This system extends wear time from 10 to 15.5 days, setting a new standard for convenience and accuracy with an overall MARD (Mean Absolute Relative Difference) of 8.0%.

Launch of Medtronic's Guardian 4 CGM Sensor in Europe
In March 2025, Medtronic launched the Guardian 4 CGM sensor in Europe, featuring a 14-day wear period and real-time alarms for glucose fluctuations. This device targets Type 1 and Type 2 diabetes patients, offering improved accuracy and integration with insulin pumps. The launch aligns with Europe's growing adoption of CGMs, supported by universal healthcare and subsidies in countries like Germany and the UK.

Conclusion:
The wearable continuous glucose monitoring devices market is poised for robust growth, projected to rise from US$12.20 billion in 2024 to US$32.48 billion by 2033 at a CAGR of 10.3%. Driven by the global diabetes epidemic, technological advancements, and increasing awareness, the market thrives, particularly in North America, which holds a 53.4% share due to its advanced healthcare infrastructure and favorable policies. Innovations like Dexcom's G7 15-Day and Abbott's Lingo expand accessibility, while sensors dominate due to their critical role. However, accuracy issues and high costs in low-income regions pose challenges.

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.